title: Use of onabotulinumtoxinA in post-traumatic oromandibular dystonia.
abstract: OBJECTIVE
  Post-traumatic oromandibular dystonia (PTOD) is a disorder whose symptoms can include bruxism, muscle pain, and involuntary muscle contraction, among others. The use of onabotulinumtoxinA (ObT-A) is helpful in controlling the symptoms of patients with PTOD. The aim of this study was to evaluate the use of ObT-A in the treatment of PTOD.
  
  
  METHODS
  In this prospective case-series study, the population consisted exclusively of patients diagnosed with PTOD, without distinction by age or gender, from January 2007 to December 2010. The patients were diagnosed with PTOD and treated with ObT-A infiltration (primary predictor) at the Department of Maxillofacial Surgery at the Hospital Clínico Mutual de Seguridad (Santiago, Chile). The primary outcome variables were bruxism, muscle pain, and involuntary muscle contraction. The data were obtained through questionnaires registered in tables at each control. Systat 13.1 was used for statistical analysis. The statistical test used to compare patients' evolution over time was the test of signs.
  
  
  RESULTS
  Thirty male patients 18 to 65 years old diagnosed with PTOD were treated with ObT-A infiltrations. The signs and symptoms associated with oromandibular dystonia (bruxism, muscle pain, and involuntary muscle contraction) were decreased in all patients after ObT-A infiltrations.
  
  
  CONCLUSIONS
  The positive results and the absence of complications recommend the use of the infiltration protocol presented in this study for the treatment of PTOD.
authors.affiliation: Maxillofacial Surgeon, Department of Maxillofacial Surgery, Hospital Clínico Mutual de Seguridad, Santiago, Chile.
authors.forename: Christian
authors.initials: C
authors.lastname: Pedemonte
authors.affiliation: Dental Surgeon, Department of Maxillofacial Surgery, Hospital Clínico Mutual de Seguridad, Santiago, Chile. Electronic address: morningrise@live.com.
authors.forename: Hernán
authors.initials: H
authors.lastname: Pérez Gutiérrez
authors.affiliation: Maxillofacial Surgeon, Department of Maxillofacial Surgery, Hospital Clínico Mutual de Seguridad, Santiago, Chile.
authors.forename: Edgardo
authors.initials: E
authors.lastname: González
authors.affiliation: Maxillofacial Surgeon, Department of Maxillofacial Surgery, Hospital Clínico Mutual de Seguridad, Santiago, Chile.
authors.forename: Ilich
authors.initials: I
authors.lastname: Vargas
authors.affiliation: Dental Surgeon, Department of Maxillofacial Surgery, Hospital Clínico Mutual de Seguridad, Santiago, Chile.
authors.forename: Diego
authors.initials: D
authors.lastname: Lazo
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D001930:Brain Injuries / Q000150:complications*; D002012:Bruxism / Q000188:drug therapy; D004421:Dystonia / Q000188:drug therapy* / Q000209:etiology; D005157:Facial Pain / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008406:Masseter Muscle / Q000187:drug effects; D008410:Masticatory Muscles / Q000187:drug effects*; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D011446:Prospective Studies; D013035:Spasm / Q000188:drug therapy; D013703:Temporal Muscle / Q000187:drug effects; D013997:Time Factors; D055815:Young Adult
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A